WASHINGTON — The Food and Drug Administration and the drug industry have jointly agreed to create several new pilot programs aimed at speeding drugs to market for rare or previously untreatable conditions.
The agreement announced Monday lays out the improvements the FDA will make in exchange for the millions of dollars it receives from drug makers who pay fees when the agency reviews their applications for new drug approvals. The industry and FDA negotiated the agreement throughout the fall and winter as part of a scheduled update to a joint agreement from five years ago.
Create a display name to comment
This name will appear with your comment